# Manolo Beelke & Partners

> Clinical Development Strategy, Global Trial Execution &  Medical Affairs


## Posts

- [The Role of Adaptive Design in Accelerating Clinical Development](https://manolobeelke.com/the-role-of-adaptive-design-in-accelerating-clinical-development/): Adaptive clinical trial design is valuable when it addresses a pre-specified uncertainty while preserving interpretability. This article covers simulation, data latency, governance, estimands and regulatory decision logic.
- [Leadership Development: Cultivating Talent in the Pharmaceutical Industry](https://manolobeelke.com/leadership-development-cultivating-talent-in-the-pharmaceutical-industry/): Pharmaceutical leadership is decision-making under scientific, operational and capital constraints. This article focuses on cross-functional judgement, productive disagreement, execution discipline and case-based capability building.
- [The Power of Strategic Consulting in Early-Stage Drug Development](https://manolobeelke.com/the-power-of-strategic-consulting-in-early-stage-drug-development/): Early-stage drug development is a sequence of capital-allocation decisions under uncertainty. This article explains how evidence sequencing, translational data, feasibility and financing logic can reduce decision-critical risk.
- [Navigating the Evolving Landscape of Clinical Trial Design](https://manolobeelke.com/navigating-the-evolving-landscape-of-clinical-trial-design/): Clinical trial design should start from the decision the study must support. This article connects endpoints, estimands, adaptive methods, real-world data, feasibility and regulatory, payer and investor evidence needs.

## Pages

- [Engagement Models](https://manolobeelke.com/how-we-work/engagement-models/): From one question to coordinated clinical delivery, the model should fit the decision, continuity and execution burden.
- [Capital & Partnering Readiness](https://manolobeelke.com/results/capital-partnering-readiness/): Investors and partners do not buy a protocol. They buy a credible risk-adjusted path to decision-grade evidence and future value.
- [Phase II/III Rescue / CNS Multi-Country](https://manolobeelke.com/results/phase-ii-iii-rescue-cns-multi-country/): Trial rescue is not cosmetic project management.
- [Pivotal Design / Rare Disease & Complex CNS](https://manolobeelke.com/results/pivotal-design-rare-disease-complex-cns/): Pivotal trials must do more than test a hypothesis.
- [Neurodegeneration / Early Development Readiness](https://manolobeelke.com/results/neurodegeneration-early-development-readiness/): Early neurodegeneration programs must generate more than safety data. They must preserve Phase II/III decision value.
- [Fundraising & Corporate Development](https://manolobeelke.com/services/fundraising-corporate-development/): We turn development logic into a financeable proposition and connect it to the right capital pathway.
- [Search MB&P](https://manolobeelke.com/search/): Search services, clinical-development decisions, academies, evidence and practical tools.
- [Should You Replace Your CRO — or Rescue the Operating Model?](https://manolobeelke.com/tools/cro-replacement-or-trial-rescue/): A clinical trial rescue decision framework for sponsors facing CRO underperformance, recruitment delay, site problems, governance failure or a possible mid-study CRO transition.
- [Tools & Diagnostics](https://manolobeelke.com/tools/): Decision-support tools for pivotal design, trial autopsy, CRO underperformance and protocol readiness—built for high-stakes clinical-development decisions.
- [Clinical Development Concept Completeness Check: Is the Study Concept Ready to Become a Protocol?](https://manolobeelke.com/tools/clinical-development-concept-completeness/): A concept sheet can contain many protocol details and still be strategically incomplete.
- [Pivotal Architecture Decision Grid: Choose the Evidence Architecture Before It Chooses Your Future](https://manolobeelke.com/tools/pivotal-architecture-decision-grid/): The pivotal architecture is not only a statistical choice.
- [Trial Autopsy: Is the Asset Failing, or Did the Trial Fail the Asset?](https://manolobeelke.com/tools/trial-autopsy/): A negative or ambiguous result does not automatically mean the biology failed.
- [Partners & Delivery Network](https://manolobeelke.com/how-we-work/partners-delivery-network/): How MB & Partners, Verum and NECTAR connect senior clinical judgment, accountable execution and qualified regional depth under one governance model.
- [Medical Affairs Strategy: Technically Strong. Strategically Marginalized.](https://manolobeelke.com/insights/publications/medical-affairs-strategy/): A structural Medical Affairs model built around scientific narrative ownership, evidence prioritisation and insight-to-action governance.
- [Fully Funded. Fully Governed.](https://manolobeelke.com/insights/publications/fully-funded-fully-governed/): A capital and governance architecture that links financing milestones to observable execution progress and protects decision value.
- [From Strategy to Controlled Execution](https://manolobeelke.com/insights/publications/from-strategy-to-controlled-execution/): A practical operating model for translating clinical-development logic into governed, decision-grade execution.
- [Publications & Evidence Library](https://manolobeelke.com/insights/publications/): Peer-reviewed research, strategic papers and public analysis organised by the decision they help readers make.
- [Terms and conditions](https://manolobeelke.com/terms-and-conditions/): Website content is provided for general professional information.
- [Privacy policy](https://manolobeelke.com/privacy-policy/): When the website is accessed, technical data such as IP address, date and time, requested resource, browser information and referring page may be processed by the hosting infrastructure to deliver and secure the service.
- [Impressum](https://manolobeelke.com/impressum/): Legal form: Sole proprietor, self-employed consultant Legal and tax name: Manolo Ernesto Beelke Trading name: Manolo Beelke & Partners Responsible proprietor: Dr.
- [Discuss the decision before it becomes a recovery project](https://manolobeelke.com/contact/): Choose the closest trigger and provide enough context to make the first exchange useful.
- [Evidence, methods and judgment](https://manolobeelke.com/insights/): Clinical-development insights, strategic papers, peer-reviewed research, case evidence and editorial series organised around the decisions they inform.
- [Evidence of judgment, not a gallery of claims](https://manolobeelke.com/results/): Anonymized cases showing how independent clinical-development judgment changes direction, reduces risk and creates real options.
- [Medical Affairs as scientific authority and evidence strategy](https://manolobeelke.com/programs/medical-affairs-strategy-academy/): who must turn scientific exchange and external insight into decisions.
- [Clinical-development judgment for people who must make programs work](https://manolobeelke.com/programs/clinical-development-excellence/): Development Excellence Canon.
- [Leadership that holds under pressure](https://manolobeelke.com/programs/arete-leadership-academy/): resilience and execution when ambiguity is high.
- [Three academies. One standard of judgment.](https://manolobeelke.com/programs/): when it matters most.
- [How clinical development strategy survives contact with reality](https://manolobeelke.com/how-we-work/): We bring together specialist expertise, evidence and disciplined governance — turning complexity into a single, clear path to meaningful outcomes.
- [Global reach, local depth, one governance model](https://manolobeelke.com/services/nectar/): MB&P defines the clinical architecture, Verum provides the accountable execution spine, and NECTAR adds qualified local delivery where it creates value.
- [Medical Affairs as scientific authority, not support theater](https://manolobeelke.com/services/medical-affairs-market-access/): medical strategy and post-launch clinical relevance.
- [Make clinical plans financeable](https://manolobeelke.com/services/investor-asset-development/): Clinical diligence and development architecture for investors, boards and companies preparing capital or partnering decisions.
- [Approval is not enough if the evidence cannot support access](https://manolobeelke.com/services/regulatory-hta-evidence-strategy/): relevance before pivotal assumptions become expensive to change.
- [Trial Rescue & Execution Governance](https://manolobeelke.com/services/trial-rescue-execution-governance/): execution before expensive failure becomes inevitable.
- [Clinical Development Strategy & Pivotal Trial Design](https://manolobeelke.com/services/clinical-development-strategy/): and protocol logic before cost, timelines and assumptions harden.
- [Fractional CMO & Medical Leadership](https://manolobeelke.com/services/fractional-cmo/): capital-facing decisions and high-stakes programme judgement.
- [Clinical development services for decisions that must hold](https://manolobeelke.com/services/): Enter through the problem you face.
- [Manolo](https://manolobeelke.com/about/manolo/): Physician-scientist. Fractional Chief Medical Officer.
- [Senior clinical development judgment, connected to controlled execution](https://manolobeelke.com/about/): MB & Partners brings together medical, regulatory, payer and operational perspectives into one accountable decision system — so the right evidence is generated, the right decisions are made, and programmes advance with confidence.
- [Clinical Development Strategy & Global Trial Execution](https://manolobeelke.com/): Science creates value only when medical strategy, regulation, trial design, execution, access, capital and leadership work as one system.


[comment]: # (Generated by Hostinger Tools Plugin)